GLP-1 agonist lixisenatide (Lyxumia®) submitted for EU approval for treatment of type-2 diabetes (NeLM news service, 4 November 2011)

07 Nov 2011


A marketing authorisation application for a GLP-1 receptor agonist, lixisenatide (Lyxumia®), has been submitted in the EU as a treatment in adults with type-2 diabetes.

Full article


Share this story